Melanoma & Skin Cancer
Meredith McKean, MD, MPH
Melanoma & Skin Cancer
Meredith McKean, MD, MPH
SCRI is coauthor on the Late Breaking Abstract, “Darovasertib Plus Crizotinib vs Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 Trial,” that will be presented on Monday, June 1 at 9:00 a.m. CDT during the session, Melanoma/Skin Cancers in S100bc.
Click here to learn more about Dr. McKean.